Repare Therapeutics Analyst Ratings
Repare Therapeutics Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/20/2023 | 367.29% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
10/16/2023 | 367.29% | Piper Sandler | $30 → $25 | Maintains | Overweight |
09/25/2023 | 217.76% | Stifel | $16 → $17 | Maintains | Buy |
08/17/2023 | 367.29% | HC Wainwright & Co. | $26 → $25 | Maintains | Buy |
06/09/2023 | 199.07% | Stifel | $11 → $16 | Upgrades | Hold → Buy |
06/09/2023 | 385.98% | HC Wainwright & Co. | $25 → $26 | Maintains | Buy |
04/27/2023 | 367.29% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
03/17/2023 | 367.29% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
02/27/2023 | 161.68% | Morgan Stanley | $15 → $14 | Maintains | Equal-Weight |
02/03/2023 | 180.37% | Morgan Stanley | $28 → $15 | Downgrades | Overweight → Equal-Weight |
11/17/2022 | 367.29% | HC Wainwright & Co. | $38 → $25 | Maintains | Buy |
08/08/2022 | 423.36% | Morgan Stanley | $30 → $28 | Maintains | Overweight |
06/06/2022 | 610.28% | HC Wainwright & Co. | $54 → $38 | Maintains | Buy |
06/02/2022 | 460.75% | Piper Sandler | $25 → $30 | Maintains | Overweight |
04/12/2022 | 105.61% | Stifel | $45 → $11 | Downgrades | Buy → Hold |
09/23/2021 | 797.2% | Stifel | → $48 | Initiates Coverage On | → Buy |
09/13/2021 | 909.35% | HC Wainwright & Co. | → $54 | Initiates Coverage On | → Buy |
08/16/2021 | 778.5% | Morgan Stanley | $45 → $47 | Maintains | Overweight |
06/28/2021 | 759.81% | Guggenheim | → $46 | Initiates Coverage On | → Buy |
04/19/2021 | 741.12% | Morgan Stanley | $41 → $45 | Maintains | Overweight |
03/01/2021 | 853.27% | Berenberg | → $51 | Initiates Coverage On | → Buy |
12/16/2020 | 666.36% | Morgan Stanley | $37 → $41 | Maintains | Overweight |
10/28/2020 | — | Northland Capital Markets | Initiates Coverage On | → Outperform | |
07/14/2020 | 591.59% | Morgan Stanley | → $37 | Initiates Coverage On | → Overweight |
07/14/2020 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
07/14/2020 | 647.66% | Piper Sandler | → $40 | Initiates Coverage On | → Overweight |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
11/20/2023 | 367.29% | HC Wainwright & Co. | → 25 美元 | 重申 | 购买 → 购买 |
2023 年 10 月 16 日 | 367.29% | 派珀·桑德勒 | 30 美元 → 25 美元 | 维护 | 超重 |
09/25/2023 | 217.76% | Stifel | 16 美元 → 17 美元 | 维护 | 买 |
08/17/2023 | 367.29% | HC Wainwright & Co. | 26 美元 → 25 美元 | 维护 | 买 |
06/09/2023 | 199.07% | Stifel | 11 美元 → 16 美元 | 升级 | 持有 → 买入 |
06/09/2023 | 385.98% | HC Wainwright & Co. | 25 美元 → 26 美元 | 维护 | 买 |
04/27/2023 | 367.29% | HC Wainwright & Co. | → 25 美元 | 重申 | → 购买 |
03/17/2023 | 367.29% | HC Wainwright & Co. | → 25 美元 | 重申 | → 购买 |
02/27/2023 | 161.68% | 摩根士丹利 | 15 美元 → 14 美元 | 维护 | 重量相等 |
02/03/2023 | 180.37% | 摩根士丹利 | 28 美元 → 15 美元 | 降级 | 超重 → 重量相等 |
11/17/2022 | 367.29% | HC Wainwright & Co. | 38 美元 → 25 美元 | 维护 | 买 |
08/08/2022 | 423.36% | 摩根士丹利 | 30 美元 → 28 美元 | 维护 | 超重 |
2022 年 6 月 6 日 | 610.28% | HC Wainwright & Co. | 54 美元 → 38 美元 | 维护 | 买 |
06/02/2022 | 460.75% | 派珀·桑德勒 | 25 美元 → 30 美元 | 维护 | 超重 |
04/12/2022 | 105.61% | Stifel | 45 美元 → 11 美元 | 降级 | 买入 → 持有 |
2021 年 9 月 23 日 | 797.2% | Stifel | → 48 美元 | 启动覆盖范围开启 | → 购买 |
09/13/2021 | 909.35% | HC Wainwright & Co. | → 54 美元 | 启动覆盖范围开启 | → 购买 |
2021 年 8 月 16 日 | 778.5% | 摩根士丹利 | 45 美元 → 47 美元 | 维护 | 超重 |
2021 年 6 月 28 日 | 759.81% | 古根海姆 | → 46 美元 | 启动覆盖范围开启 | → 购买 |
2021 年 4 月 19 日 | 741.12% | 摩根士丹利 | 41 美元 → 45 美元 | 维护 | 超重 |
2021 年 1 月 3 日 | 853.27% | 贝伦贝格 | → 51 美元 | 启动覆盖范围开启 | → 购买 |
2020 年 12 月 16 日 | 666.36% | 摩根士丹利 | 37 美元 → 41 美元 | 维护 | 超重 |
10/28/2020 | — | 北国资本市场 | 启动覆盖范围开启 | → 跑赢大盘 | |
2020 年 7 月 14 日 | 591.59% | 摩根士丹利 | → 37 美元 | 启动覆盖范围开启 | → 超重 |
2020 年 7 月 14 日 | — | Cowen & Co. | 启动覆盖范围开启 | → 跑赢大盘 | |
2020 年 7 月 14 日 | 647.66% | 派珀·桑德勒 | → 40 美元 | 启动覆盖范围开启 | → 超重 |
What is the target price for Repare Therapeutics (RPTX)?
Repare Therapeutics(RPTX)的目标价格是多少?
The latest price target for Repare Therapeutics (NASDAQ: RPTX) was reported by HC Wainwright & Co. on November 20, 2023. The analyst firm set a price target for $25.00 expecting RPTX to rise to within 12 months (a possible 367.29% upside). 10 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年11月20日公布了Repare Therapeutics(纳斯达克股票代码:RPTX)的最新目标股价。该分析公司将目标股价定为25.00美元,预计RPTX将在12个月内升至12个月内(可能上涨367.29%)。去年有10家分析公司公布了评级。
What is the most recent analyst rating for Repare Therapeutics (RPTX)?
分析师对Repare Therapeutics(RPTX)的最新评级是多少?
The latest analyst rating for Repare Therapeutics (NASDAQ: RPTX) was provided by HC Wainwright & Co., and Repare Therapeutics reiterated their buy rating.
HC Wainwright & Co. 提供了Repare Therapeutics(纳斯达克股票代码:RPTX)的最新分析师评级,Repare Therapeutics重申了买入评级。
When is the next analyst rating going to be posted or updated for Repare Therapeutics (RPTX)?
Repare Therapeutics(RPTX)的下一个分析师评级何时公布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Repare Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Repare Therapeutics was filed on November 20, 2023 so you should expect the next rating to be made available sometime around November 20, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与Repare Therapeutics的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月做一次这样的评级,因此每家公司每年应该获得4次评级。Repare Therapeutics的最新评级是在2023年11月20日公布的,因此您应该预计下一个评级将在2024年11月20日左右公布。
Is the Analyst Rating Repare Therapeutics (RPTX) correct?
分析师对 Repare Therapeutics (RPTX) 的评级正确吗?
While ratings are subjective and will change, the latest Repare Therapeutics (RPTX) rating was a reiterated with a price target of $0.00 to $25.00. The current price Repare Therapeutics (RPTX) is trading at is $5.35, which is within the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但重申了最新的Repare Therapeutics(RPTX)评级,目标股价为0.00美元至25.00美元。Repare Therapeutics(RPTX)目前的交易价格为5.35美元,在分析师的预测区间内。